GMAB Stock Forecast & Price Target

Genmab is viewed favorably because its business is anchored by Darzalex royalties, which generated $966M in 2025 royalty revenue and support a profitable, cash-generative base with about $1.5B in cash, cash equivalents, and marketable securities at 2Q26. The company’s 1H26 revenue rose 25% year over year to $2,051M, and management raised 2026 guidance as Epkinly and the broader royalty portfolio continued to accelerate. Beyond the core franchise, a late-stage pipeline with Rina-S, petosemtamab, and epcoritamab offers multiple near-term catalysts, including 5 active or planned Phase 3 studies in ovarian and endometrial cancer and several pivotal readouts in 4Q26.

Genmab is exposed to meaningful downside from R&D, regulatory, legal, and commercial setbacks that could delay or weaken pipeline progress and reduce confidence in its oncology franchise. Its dependence on partnered products such as Darzalex, Tepezza, Kesimpta, Rybrevant, Tivdak, and Epkinly also leaves it vulnerable to lower-than-expected product sales and shifting partner priorities, while new competitors could pressure market share. Added financing risk from the Merus acquisition and associated debt financing further clouds the outlook by increasing balance-sheet and execution uncertainty.